Health care personnel (HCP) are at increased risk for infection with SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), as a result of their exposure to patients or community contacts with COVID-19 (1,2). Since the first confirmed case of COVID-19 in Minnesota was reported on March 6, 2020, the Minnesota Department of Health (MDH) has required health care facilities* to report HCP † exposures to persons with confirmed COVID-19 for exposure risk assessment and to enroll HCP with higher-risk exposures into quarantine and symptom monitoring. During March 6-July 11, MDH and 1,217 partnering health care facilities assessed 21,406 HCP exposures; among these, 5,374 (25%) were classified as higher-risk § (3). Higher-risk exposures involved direct patient care (66%) and nonpatient care interactions (e.g., with coworkers and social and household contacts) (34%). Within 14 days following a higher-risk exposure, nearly one third (31%) of HCP who were enrolled in monitoring reported COVID-19-like symptoms, ¶ and more than one half (52%) of enrolled HCP with symptoms received positive * Health care facilities as defined by MDH include acute care hospitals, critical access hospitals, long-term acute care hospitals, skilled nursing facilities, assisted living facilities, group homes, adult foster care, treatment facilities, dialysis centers, outpatient clinics, dental clinics, home health care, and hospice. † HCP as defined by MDH include, but are not limited to, emergency medical service personnel, nurses, nursing assistants, physicians, technicians, therapists, phlebotomists, pharmacists, students and trainees, contractual staff members not employed by the health care facility, and persons not directly involved in patient care, but who could be exposed to infectious agents that can be transmitted in the health care setting (e.g., clerical, dietary, environmental services, laundry, security, engineering and facilities management, administrative, billing, and volunteer personnel). HCP does not include clinical laboratory personnel. § During February 8-May 18, 2020, CDC exposure risk assessment guidance included medium-and high-risk categories, with risk level based on PPE worn and type of potential contact with a person with confirmed COVID-19. On May 19, CDC's risk assessment was updated to include a single higher-risk exposure category to include close (within 6 feet), prolonged (≥15 minutes or of any duration during an aerosol-generating procedure) contact with a person with confirmed COVID

No abstract

ABSTRACT. Capsular retraction is an infrequent but characteristic feature of malignant liver lesions such as hepatic metastases and intrahepatic cholangiocarcinoma. Rarely, this finding may be observed in association with benign lesions, such as atypical haemangiomas. Capsular retraction has not previously been reported in association with hepatic inflammatory pseudotumour (IPT). Hepatic IPT is an uncommon benign hepatic lesion with a good clinical prognosis. In this report, we discuss the case of a 48-year-old woman with capsular retraction secondary to multifocal hepatic inflammatory IPTs. Case reportA 48-year-old woman presented with a 2-year history of intermittent right-upper quadrant abdominal pain. She denied any history of fever, chills, diarrhoea or haematochezia. Physical examination of the abdomen was unremarkable. Routine haematological studies were normal. Alanine aminotransferase, alkaline phosphatase and c-glutamyl transferase levels were mildly elevated. Aspartate aminotransferase, serum albumin, bilirubin and a-fetoprotein levels were within normal limits. Serological tests revealed elevated C-reactive protein and immunoglobulin (Ig)G (elevated IgG subclasses 1 and 2) levels, but were negative for anti-mitochondrial antibody, anti-nuclear antibody, anti-smooth muscle antibody and hepatitis B and C viral markers.Contrast-enhanced CT of the abdomen revealed multiple homogeneously enhancing lesions distributed throughout the liver. The largest enhancing lesion, measuring 1.9 6 1.6 cm, was surrounded by a 1 cm zone of relative fat sparing in Segment III in a subcapsular location and was associated with focal concavity of the anterior and inferior surface of the overlying liver (Figure 1). The other lesions ranged from 3-12 mm in diameter. The liver was severely steatotic. Follow-up double contrast-enhanced MRI (Sigma; General Electric Medical Systems, Milwaukee, WI) was performed at 3T to further characterise the lesions. All lesions were hypointense relative to the surrounding liver on T 1 weighted in-phase and T 2 weighted unenhanced images.

No abstract

No abstract